CD4 and neoplasm: Another major challenge for the selection of the best targets for a CD4+ T-cell-based immunotherapy is to identify which of the immunogenic neo-epitopes are generated by the MHC class II processing machinery and displayed by the tumor cells for T-cell recognition.